{"id":389892,"date":"2020-11-30T16:08:07","date_gmt":"2020-11-30T21:08:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=389892"},"modified":"2020-11-30T16:08:07","modified_gmt":"2020-11-30T21:08:07","slug":"quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/","title":{"rendered":"Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data"},"content":{"rendered":"
\n

JERSEY, Channel Islands, Nov. 30, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray. The data suggest that tests performed with Quotient’s Microarray are highly accurate.<\/p>\n

\n Expanded IH Microarray <\/strong>
\n Preliminary <\/strong>
\n Performance<\/strong>\n <\/p>\n

To date in the EU field trial, over 4000 randomly selected human blood donor samples have been tested. The concordance data obtained through the study are as follows:<\/p>\n\n\n\n\n\n
Antigen Type<\/td>\nA<\/td>\nB<\/td>\nD<\/td>\nC<\/td>\nc<\/td>\nE<\/td>\ne<\/td>\nK<\/td>\nCw<\/sup><\/td>\n<\/tr>\n
Concordance<\/td>\n100%<\/td>\n100%<\/td>\n99%<\/td>\n99%<\/td>\n99%<\/td>\n100%<\/td>\n100%<\/td>\n100%<\/td>\n100%<\/td>\n<\/tr>\n
Antigen Type<\/td>\nk<\/td>\nKpa<\/sup><\/td>\nFyb<\/sup><\/td>\nJka<\/sup><\/td>\nJkb<\/sup><\/td>\nS<\/td>\nLeb<\/sup><\/td>\nAntibody Screen<\/td>\n<\/tr>\n
Concordance<\/td>\n100%<\/td>\n98%<\/td>\n98%<\/td>\n99%<\/td>\n96%<\/td>\n99%<\/td>\n99%<\/td>\n97%<\/td>\n<\/tr>\n<\/table>\n

The preliminary field trial data were obtained in testing laboratories using microarrays manufactured in Quotient\u2019s ISO certified manufacturing facility in combination with the CE marked MosaiQ instrument.<\/p>\n

The Company plans to make a CE mark submission for the Expanded IH microarray around year end. \u201cWe decided to seek two separate CE Marks – one covering all the tests included in the expanded IH menu and one with a more basic menu. This will allow us to respond more flexibly to individual tenders in Europe. We are on track to have the first powerful commercial combination, Expanded IH and Initial SDS, available for sale in Europe during the second quarter of calendar year 2021,\u201d said Franz Walt, Chief Executive Officer of Quotient.<\/p>\n

Quotient also reported that it expects to shortly begin a US field trial for the Expanded IH Microarray and that initial results from that trial are expected by mid-2021.<\/p>\n

\n About Quotient Limited<\/strong>\n <\/p>\n

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient\u2019s proprietary multiplex microarray technology, offers the world\u2019s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient’s operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.<\/p>\n

\n Contact:<\/strong> Peter Buhler, Chief Financial Officer, IR@quotientbd.com; +41 22 545 52 26<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

JERSEY, Channel Islands, Nov. 30, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray. The data suggest that tests performed with Quotient’s Microarray are highly accurate. Expanded IH Microarray Preliminary Performance To date in the EU field trial, over 4000 randomly selected human blood donor samples have been tested. The concordance data obtained through the study are as follows: Antigen Type A B D C c E e K Cw Concordance 100% 100% 99% 99% 99% 100% 100% 100% 100% Antigen Type k Kpa Fyb Jka Jkb S Leb Antibody Screen Concordance 100% 98% 98% 99% 96% 99% 99% 97% The … <\/p>\n

Continue reading “Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-389892","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nQuotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"JERSEY, Channel Islands, Nov. 30, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray. The data suggest that tests performed with Quotient’s Microarray are highly accurate. Expanded IH Microarray Preliminary Performance To date in the EU field trial, over 4000 randomly selected human blood donor samples have been tested. The concordance data obtained through the study are as follows: Antigen Type A B D C c E e K Cw Concordance 100% 100% 99% 99% 99% 100% 100% 100% 100% Antigen Type k Kpa Fyb Jka Jkb S Leb Antibody Screen Concordance 100% 98% 98% 99% 96% 99% 99% 97% The … Continue reading "Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T21:08:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDAyOCMzODQ4OTE2IzIwMjc0MzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data\",\"datePublished\":\"2020-11-30T21:08:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/\"},\"wordCount\":366,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDAyOCMzODQ4OTE2IzIwMjc0MzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/\",\"name\":\"Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDAyOCMzODQ4OTE2IzIwMjc0MzU=\",\"datePublished\":\"2020-11-30T21:08:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDAyOCMzODQ4OTE2IzIwMjc0MzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NDAyOCMzODQ4OTE2IzIwMjc0MzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/","og_locale":"en_US","og_type":"article","og_title":"Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data - Market Newsdesk","og_description":"JERSEY, Channel Islands, Nov. 30, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray. The data suggest that tests performed with Quotient’s Microarray are highly accurate. Expanded IH Microarray Preliminary Performance To date in the EU field trial, over 4000 randomly selected human blood donor samples have been tested. The concordance data obtained through the study are as follows: Antigen Type A B D C c E e K Cw Concordance 100% 100% 99% 99% 99% 100% 100% 100% 100% Antigen Type k Kpa Fyb Jka Jkb S Leb Antibody Screen Concordance 100% 98% 98% 99% 96% 99% 99% 97% The … Continue reading \"Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-30T21:08:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDAyOCMzODQ4OTE2IzIwMjc0MzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data","datePublished":"2020-11-30T21:08:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/"},"wordCount":366,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDAyOCMzODQ4OTE2IzIwMjc0MzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/","name":"Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDAyOCMzODQ4OTE2IzIwMjc0MzU=","datePublished":"2020-11-30T21:08:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDAyOCMzODQ4OTE2IzIwMjc0MzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NDAyOCMzODQ4OTE2IzIwMjc0MzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/quotient-limited-announces-mosaiq-expanded-ih-eu-field-trial-performance-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Quotient Limited Announces MosaiQ\u2122 Expanded IH EU Field Trial Performance Data"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=389892"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389892\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=389892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=389892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=389892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}